[PDF] [PDF] Investor Presentation - ResMed - Investor Relations

[PDF] INVESTOR PRESENTATION

Reported financial results referenced in this presentation for years 2015 and prior do not reflect the adoption of the new revenue recognition standards that went 

[PDF] INVESTOR PRESENTATION - REE

3 fév 2021 · (“REE”) and 10X Capital Venture Acquisition Corp (“10X”) and related transactions (the "Transaction") and for no other purpose No 

[PDF] Investor Presentation - ResMed - Investor Relations

Please consult the users' manual for further information Page 24 ©ResMed 2014 I Horizon 2: Full spectrum of ventilation products

[PDF] INVESTOR PRESENTATION JANUARY 2021 - Astra

2 fév 2021 · Investors and security holders of HOL are advised to read, when available, the proxy statement/prospectus in connection with HOL's solicitation of 

[PDF] Investor Presentation - Forum Merger Corporation

16 fév 2021 · This investor presentation (the “presentation”) is for information purposes only to assist interested parties in making their own evaluation with 

[PDF] Investor Presentation - GigCapital

9 déc 2020 · (“Lightning eMotors”, “Lightning Systems”, the “Company”, “us”, “our” or “we”) and GigCapital3, Inc , a special purpose acquisition company (“Gig3 

[PDF] Volta - Tortoise II - Investor Presentation - 020821

You should review the investors presentation and perform your own due diligence, prior to making an investment in Tortoise II and Volta Risks Related to  

[PDF] Investor Presentation 3Q20

Investor Presentation 3Q20 Page 2 2 Disclaimer This presentation has been prepared by Cango Inc (the “Company”) solely for Manual Evaluation If

[PDF] INVESTOR PRESENTATION - Squarespace

14 août 2020 · HCAC and Canoo believe these non-GAAP measures of financial results provide useful information to management and investors regarding 

[PDF] investor presentation ppt template

[PDF] invité politique dimanche france inter

[PDF] invité politique matinale france inter

[PDF] invoice declaration

[PDF] involuntary servitude

[PDF] inward mc delivered no signature

[PDF] io sono francese in inglese traduzione

[PDF] iodine test for starch

[PDF] iodoform test for alcohols

[PDF] iolani boarding school

[PDF] iolani family handbook 2019 2020

[PDF] iolani school course

[PDF] iolani school english

[PDF] iolani school headmaster's list

[PDF] iolani school principal

Investor Presentation

Q3 2015

June 10, 2015

©ResMed 2014 I

FORWARD LOOKING STATEMENTS

Statements contained in this presentation -

of 1995. These forward-looking statements -- including statements regarding ResMed's projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products -- are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and Securities & Exchange Commission. ResMed does not undertake to update its forward- looking statements. 2

©ResMed 2014 I

3

WHO WE ARE

WHY INVEST

WHERE WE'RE GOING

©ResMed 2014 I

Overview

Operate in more than 100 countries directly and with distribution partners

Integrated global manufacturing operations:

Australia, France, Singapore, and USA

Invest ~7% of revenue in R&D

More than 5,000 patents and designs

FY 2014 annual revenue > US$1.5 billion

Over 4,000 employees world-wide

Listed: New York Stock Exchange (NYSE) and in Australia (ASX) 4 Leading global developer, manufacturer and marketer of medical solutions to treat and manage sleep-disordered breathing, chronic obstructive pulmonary disease and other chronic respiratory conditions.

©ResMed 2014 I

Improve quality-of-life for patients

Prevent chronic disease progression

Reduce costs of managing chronic disease

5 Holy Grail: Improve outcomes & reduce healthcare costs

©ResMed 2014 I

Opportunity to shift care from hospital to home

Source: OECD report (2011) - WHY IS HEALTH SPENDING IN THE UNITED STATES SO HIGH? www.oecd.org 6

©ResMed 2014 I

MMWR, Vol 60, 2011

CVD & Stroke

$403 billion

Obstructive Sleep Apnea

Obesity

Diabetes

Asthma

$165 billion* $147 billion $145 billion $20 billion

We can reduce costs of key chronic diseases

Annual costs per chronic condition

7

CDC National Asthma

Control Program

CDC, National Diabetes

Fact Sheet, 2011

Eric A. Finkelstein, et al, Health

Affairs 28, no. 5 (2009): w822-w831

McKinsey & Company analysis

Harvard Medical School, 2010

©ResMed 2014 I

8

WHO WE ARE

WHY INVEST

WHERE WE'RE GOING

©ResMed 2014 I

Why invest

9 Strong Portfolio Strong Performance Growth Drivers

ƒBroad range of

products & solutions

Wireless, cloud-

connected devices

End-to-end patient

management solutions

Consumer sleep

wellness offerings

ƒOver 100 countries

ƒSolid revenue growth

track-record

ƒOperational excellence

is part of our DNA

ƒStrong cash flow

ƒActive capital

management - share repurchase, dividends

ƒUnderpenetrated

global SDB market

ƒNew adjacent markets

in COPD, CAD & AF

ƒEmerging markets in

China, India and Brazil

ƒProduct and service

innovation

©ResMed 2014 I

Key Financial Metrics Q3 2015

Revenue $422M

+6% (13% CC)

Gross margin 59.5%

GAAP net income $91M

+1%

Non-GAAP EPS $0.65

+2%

GAAP EPS $0.64

+2%

Operating profit $106M

Cash flow from operations $91M

Free cash flow $80M

Q3 2015 Results

10

©ResMed 2014 I

Diversified revenue sources by region & product

11

Americas

59%

Europe

31%

Asia-Pacific

10%

Masks and

Accessories

41%
Flow

Generators

59%

©ResMed 2014 I

Strong financial performance

12

Revenue Net Income

EPS $0.9 $1.6

20092014

11% CAGR (USD in Billions, except EPS) $0.1 $0.3

20092014

19% CAGR $0.95 $2.42

20092014

21%
CAGR $0.1 $0.3

20092014

20% CAGR

Free Cash Flow

©ResMed 2014 I

Robust capital management

13

Capital Deployment

FCF returned to

Shareholders

ƒYTD 2015 combined dividend

and stock repurchase = 92% of free cash flow

ƒYTD 2015 Dividend payout

ratio of 44% of net income

ƒ2015 dividend per share

increased 11% over prior year

Increasing Dividend

Investment for Growth

ƒNew products

ƒGeographic expansion

ƒAcquisitions

Combined dividend and buy-back over rolling 5 years = 98% of free cash flow

©ResMed 2014 I

14

WHO WE ARE

WHY INVEST

WHERE WE'RE GOING

©ResMed 2014 I

Three Horizon Growth Strategy

15

Patient Growth

Time

Changing lives with every breath

20 million lives changed by 2020

Improve patient quality of life

Prevent chronic disease progression

Reduce healthcare system costs Horizon 3

Accelerate and Expand

into New Markets

Horizon 2

Scale-Up Respiratory Care and

Grow in Emerging Markets

Horizon 1

Lead SDB Industry

Ground breaking end-to-

end solutions

Adjacent growth in COPD,

OHS, NMD, including ALS

Emerging markets growth

in China, India and Brazil

Respiratory monitoring

solutions for HF & COPD

Cardiology

௅Coronary Artery Disease ௅Atrial Fibrillation

©ResMed 2014 I

Horizon 1: We changed the basis of competition

16 DIAGNOSIS THERAPY MONITORING & MGMT. PATIENT ENGAGEMENT BILLING

©ResMed 2014 I

quotesdbs_dbs20.pdfusesText_26